<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="6de414b1-f707-4b98-9e4b-742032ec90af"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Umeclidinium and Vilanterol ELLIPTA safely and effectively.  See full prescribing information for Umeclidinium and Vilanterol ELLIPTA.<br/>
      <br/>Umeclidinium and Vilanterol ELLIPTA inhalation powder, for oral inhalation use<br/>Initial U.S. Approval: 2013</title>
   <effectiveTime value="20241122"/>
   <setId root="6de414b1-f707-4b98-9e4b-742032ec90af"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="065969375" root="1.3.6.1.4.1.519.1"/>
            <name>Prasco Laboratories</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="167380711" root="1.3.6.1.4.1.519.1"/>
                  <name>GlaxoSmithKline LLC</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="11933b32-8f7c-4bc3-b315-690f57607a60"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20241122"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="66993-134"/>
                        <name>Umeclidinium and Villanterol Ellipta</name>
                        <formCode code="C42972" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>umeclidinium bromide and vilanterol trifenatate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="ug" value="62.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7AN603V4JV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>UMECLIDINIUM BROMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="GE2T1418SV" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>UMECLIDINIUM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="ug" value="25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="40AHO2C6DG" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VILANTEROL TRIFENATATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="028LZY775B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VILANTEROL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C16738" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INHALER"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="66993-134-97" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20250411"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA203975" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250411"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_81234790-4edc-4809-b7a0-a4e6bf81a3ba">
               <id root="2dfc27a9-dbc6-4946-9d22-88685701fd0d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Umeclidinium and Vilanterol ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use</content>
                  </paragraph>
                  <paragraph>Umeclidinium and Vilanterol ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of Umeclidinium and Vilanterol ELLIPTA in asthma have not been established.</paragraph>
               </text>
               <effectiveTime value="20241122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Umeclidinium and Vilanterol ELLIPTA is a combination of umeclidinium, an anticholinergic, and vilanterol, a long-acting beta<sub>2</sub>-adrenergic agonist (LABA), indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). (<linkHtml href="#ID_81234790-4edc-4809-b7a0-a4e6bf81a3ba">1</linkHtml>)</paragraph>
                        <paragraph>Limitations of Use: Not indicated for relief of acute bronchospasm or for the treatment of asthma. (<linkHtml href="#ID_81234790-4edc-4809-b7a0-a4e6bf81a3ba">1</linkHtml>, <linkHtml href="#ID_2621e6b9-9be8-4231-bc8e-56a543330c04">5.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_749b5c7e-ae64-4cbe-8b8b-274fbcf4fdd9">
               <id root="858de22d-2b12-4c17-867e-94ad64845520"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <text>
                  <paragraph>The recommended dosage of Umeclidinium and Vilanterol ELLIPTA for maintenance treatment of COPD is 62.5 mcg umeclidinium and 25 mcg vilanterol (1 actuation of Umeclidinium and Vilanterol ELLIPTA 62.5/25 mcg) once daily by oral inhalation.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Umeclidinium and Vilanterol ELLIPTA should be used at the same time every day. Do not use Umeclidinium and Vilanterol ELLIPTA more than 1 time every 24 hours.</item>
                     <item>
                        <caption>•</caption>No dosage adjustment is required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_1fbb18d8-0022-4654-82d3-a564b203ac81">12.3</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20241122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>For oral inhalation only. (<linkHtml href="#ID_749b5c7e-ae64-4cbe-8b8b-274fbcf4fdd9">2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Maintenance treatment of COPD: 1 actuation of Umeclidinium and Vilanterol ELLIPTA once daily administered by oral inhalation. (<linkHtml href="#ID_749b5c7e-ae64-4cbe-8b8b-274fbcf4fdd9">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_10375dbb-e655-42a4-a3bc-507dd8b49750">
               <id root="e16814e7-6874-4b8e-925a-100cdbe39bcf"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Inhalation powder: 62.5 mcg umeclidinium and 25 mcg vilanterol (62.5/25 mcg) per actuation.</paragraph>
               </text>
               <effectiveTime value="20241122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Inhalation powder: 62.5 mcg umeclidinium and 25 mcg vilanterol (62.5/25 mcg) per actuation. (<linkHtml href="#ID_10375dbb-e655-42a4-a3bc-507dd8b49750">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_e70fa47e-d5c3-401f-8a2f-7298d8aab16f">
               <id root="e7cc949f-b694-4774-954e-c01fab824368"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Umeclidinium and Vilanterol ELLIPTA is contraindicated in:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to umeclidinium, vilanterol, or any of the excipients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_1a2c09b0-04ae-4769-b987-ed11edc88337">5.6</linkHtml>), Description (<linkHtml href="#ID_8fa6a58e-4c3b-4661-83ef-08bfab1c4c64">11</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>use of a long-acting beta<sub>2</sub>-adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_d5ab7664-739f-4bf6-974e-42cb02984dbc">5.1</linkHtml>)]</content>. Umeclidinium and Vilanterol ELLIPTA is not indicated for the treatment of asthma.</item>
                  </list>
               </text>
               <effectiveTime value="20241122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Severe hypersensitivity to milk proteins or any ingredients. (<linkHtml href="#ID_e70fa47e-d5c3-401f-8a2f-7298d8aab16f">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Use of a LABA, including Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid is contraindicated in patients with asthma. (<linkHtml href="#ID_e70fa47e-d5c3-401f-8a2f-7298d8aab16f">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_62aa6e20-d388-4ed4-95c5-d02f9488e2a1">
               <id root="8318a2f1-c4ae-493e-8e31-018d125a89ea"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20241122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>LABA monotherapy (without an inhaled corticosteroid) for asthma increases the risk of serious asthma-related events. (<linkHtml href="#ID_d5ab7664-739f-4bf6-974e-42cb02984dbc">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Do not initiate in acutely deteriorating COPD. Do not use to treat acute symptoms. (<linkHtml href="#ID_2621e6b9-9be8-4231-bc8e-56a543330c04">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Do not use in combination with additional therapy containing a LABA because of risk of overdose. (<linkHtml href="#ID_bff5ade5-dfa2-43d0-80c1-1dd0e1aa39d9">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>If paradoxical bronchospasm occurs, discontinue Umeclidinium and Vilanterol ELLIPTA and institute alternative therapy. (<linkHtml href="#ID_de2b81e6-745f-4002-a8fd-82e7f4e278d5">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Use with caution in patients with cardiovascular disorders because of beta-adrenergic stimulation. (<linkHtml href="#ID_5c924790-f375-4ce5-8a1b-7229b1d1b7d7">5.7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis. (<linkHtml href="#ID_3b93ed87-1c06-42f2-aa8c-e380a7f54d1a">5.8</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Worsening of narrow-angle glaucoma may occur. Use with caution in patients with narrow-angle glaucoma and instruct patients to contact a healthcare provider immediately if symptoms occur. (<linkHtml href="#ID_bef45778-2b90-49af-9066-2b9c5dd2542e">5.9</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur. (<linkHtml href="#ID_907ec43d-b6d5-4f5c-aa36-fdf18a15b99e">5.10</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Be alert to hypokalemia and hyperglycemia. (<linkHtml href="#ID_97dd4856-74e9-4814-bae1-0139d969bc23">5.11</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_d5ab7664-739f-4bf6-974e-42cb02984dbc">
                     <id root="68414676-f3ae-40ad-80a5-f373a166c0bf"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Serious Asthma-Related Events – Hospitalizations, Intubations, Death </title>
                     <text>
                        <paragraph>The safety and effectiveness of Umeclidinium and Vilanterol ELLIPTA in patients with asthma have not been established. Umeclidinium and Vilanterol ELLIPTA is not indicated for the treatment of asthma <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_e70fa47e-d5c3-401f-8a2f-7298d8aab16f">4</linkHtml>)]</content>.</paragraph>
                        <paragraph>Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Salmeterol Multicenter Asthma Research Trial (SMART)</content>
                        </paragraph>
                        <paragraph>A 28-week, placebo-controlled, U.S. trial that compared the safety of another LABA (salmeterol) with placebo, each added to usual asthma therapy, showed an increase in asthma‑related deaths in subjects receiving salmeterol (13/13,176 in subjects treated with salmeterol vs. 3/13,179 in subjects treated with placebo; relative risk: 4.37 [95% CI: 1.25, 15.34]). The increased risk of asthma-related death is considered a class effect of LABAs, including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA.</paragraph>
                        <paragraph>No trial adequate to determine whether the rate of asthma-related death is increased in subjects treated with Umeclidinium and Vilanterol ELLIPTA has been conducted.</paragraph>
                        <paragraph>Available data do not suggest an increased risk of death with use of LABA in patients with COPD.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2621e6b9-9be8-4231-bc8e-56a543330c04">
                     <id root="e5cddeff-0d1f-4555-8ae5-d664d5e9f05c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Deterioration of Disease and Acute Episodes </title>
                     <text>
                        <paragraph>Umeclidinium and Vilanterol ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD. Umeclidinium and Vilanterol ELLIPTA has not been studied in subjects with acutely deteriorating COPD. The initiation of Umeclidinium and Vilanterol ELLIPTA in this setting is not appropriate.</paragraph>
                        <paragraph>If Umeclidinium and Vilanterol ELLIPTA no longer controls symptoms of bronchoconstriction; the patient’s inhaled, short-acting beta<sub>2</sub>-agonist becomes less effective; or the patient needs more short-acting beta<sub>2</sub>‑agonist than usual, these may be markers of deterioration of disease. In this setting, re‑evaluate the patient and the COPD treatment regimen at once. The daily dose of Umeclidinium and Vilanterol ELLIPTA should not be increased. Increasing use of inhaled, short-acting beta<sub>2</sub>-agonists is a signal of deteriorating disease. In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the need for additional therapeutic options. Patients should not use more than 1 inhalation of Umeclidinium and Vilanterol ELLIPTA once daily.</paragraph>
                        <paragraph>Umeclidinium and Vilanterol ELLIPTA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Umeclidinium and Vilanterol ELLIPTA has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta<sub>2</sub>-agonist.</paragraph>
                        <paragraph>When beginning treatment with Umeclidinium and Vilanterol ELLIPTA, patients who have been taking oral or inhaled, short-acting beta<sub>2</sub>-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs and to use them only for symptomatic relief of acute respiratory symptoms. When prescribing Umeclidinium and Vilanterol ELLIPTA, the healthcare provider should also prescribe an inhaled, short-acting beta<sub>2</sub>-agonist and instruct the patient on how it should be used.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bff5ade5-dfa2-43d0-80c1-1dd0e1aa39d9">
                     <id root="d571f35d-505e-430a-a78d-dd8e950a2e8c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Avoid Excessive Use of Umeclidinium and Vilanterol ELLIPTA and Avoid Use with Other Long-Acting Beta<sub>2</sub>-Agonists </title>
                     <text>
                        <paragraph>Umeclidinium and Vilanterol ELLIPTA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other therapies containing LABAs, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using Umeclidinium and Vilanterol ELLIPTA should not use another therapy containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3d3b7131-9c57-400e-877d-64b91012e7fd">
                     <id root="577d4055-9f7f-49ea-842c-ee02c70113c5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors </title>
                     <text>
                        <paragraph>Caution should be exercised when considering the coadministration of Umeclidinium and Vilanterol ELLIPTA with ketoconazole and other known strong cytochrome P450 3A4 (CYP3A4) inhibitors (including, but not limited to, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased cardiovascular adverse effects may occur <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_33db6343-f676-4060-99d3-e5c34280d265">7.1</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_1fbb18d8-0022-4654-82d3-a564b203ac81">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_de2b81e6-745f-4002-a8fd-82e7f4e278d5">
                     <id root="5924ab7a-a68a-4c1a-a1b3-66c641fe9b78"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Paradoxical Bronchospasm </title>
                     <text>
                        <paragraph>As with other inhaled therapies, Umeclidinium and Vilanterol ELLIPTA can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with Umeclidinium and Vilanterol ELLIPTA, it should be treated immediately with an inhaled, short-acting bronchodilator; Umeclidinium and Vilanterol ELLIPTA should be discontinued immediately; and alternative therapy should be instituted.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1a2c09b0-04ae-4769-b987-ed11edc88337">
                     <id root="49b65524-9afc-48eb-99d7-804d1286d2c9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Hypersensitivity Reactions, including Anaphylaxis </title>
                     <text>
                        <paragraph>Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of Umeclidinium and Vilanterol ELLIPTA. Discontinue Umeclidinium and Vilanterol ELLIPTA if such reactions occur. There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of other powder medications containing lactose; therefore, patients with severe milk protein allergy should not use Umeclidinium and Vilanterol ELLIPTA <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_e70fa47e-d5c3-401f-8a2f-7298d8aab16f">4</linkHtml>), Adverse Reactions (<linkHtml href="#ID_60c285b5-e3e1-4484-b283-5a09a21f6da0">6.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5c924790-f375-4ce5-8a1b-7229b1d1b7d7">
                     <id root="020c00f9-c3c7-41d4-b7a4-7e4b260d0c07"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Cardiovascular Effects </title>
                     <text>
                        <paragraph>Vilanterol, like other beta<sub>2</sub>-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles. If such effects occur, Umeclidinium and Vilanterol ELLIPTA may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_dfbed26b-6d5d-4a41-bf31-7eb1f792c677">12.2</linkHtml>)]</content>. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.</paragraph>
                        <paragraph>Umeclidinium and Vilanterol ELLIPTA, like other sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.</paragraph>
                        <paragraph>In a 52-week trial of subjects with COPD, the exposure-adjusted rates for any on-treatment major adverse cardiac event, including non-fatal central nervous system hemorrhages and cerebrovascular conditions, non-fatal myocardial infarction, non-fatal acute myocardial infarction, and adjudicated on-treatment death due to cardiovascular events, was 2.2 per 100 patient-years for fluticasone furoate/umeclidinium/vilanterol 100/62.5/25 mcg (n = 4,151), 1.9 per 100 patient-years for fluticasone furoate/vilanterol 100/25 mcg (n = 4,134), and 2.2 per 100 patient-years for umeclidinium and vilanterol ELLIPTA (n = 2,070). Adjudicated on‑treatment deaths due to cardiovascular events occurred in 20 of 4,151 patients (0.54 per 100 patient-years) receiving fluticasone furoate/umeclidinium/vilanterol, 27 of 4,134 patients (0.78 per 100 patient-years) receiving fluticasone furoate/vilanterol, and 16 of 2,070 patients (0.94 per 100 patient-years) receiving umeclidinium and vilanterol ELLIPTA.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3b93ed87-1c06-42f2-aa8c-e380a7f54d1a">
                     <id root="00509394-6a25-4d88-bc1d-abf5027926e2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8	Coexisting Conditions </title>
                     <text>
                        <paragraph>Umeclidinium and Vilanterol ELLIPTA, like all therapies containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Doses of the related beta<sub>2</sub>-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bef45778-2b90-49af-9066-2b9c5dd2542e">
                     <id root="e2a03ffa-da1e-470f-894f-1a2af5177360"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9	Worsening of Narrow-Angle Glaucoma </title>
                     <text>
                        <paragraph>Umeclidinium and Vilanterol ELLIPTA should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should also be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos, or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a healthcare provider immediately if any of these signs or symptoms develop.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_907ec43d-b6d5-4f5c-aa36-fdf18a15b99e">
                     <id root="a9ea0bc7-6859-4885-8a0e-f052fc168a42"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10	Worsening of Urinary Retention </title>
                     <text>
                        <paragraph>Umeclidinium and Vilanterol ELLIPTA, like all therapies containing an anticholinergic, should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a healthcare provider immediately if any of these signs or symptoms develop.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_97dd4856-74e9-4814-bae1-0139d969bc23">
                     <id root="ad5d8579-2c76-4f0c-87a3-44662f6e1731"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11	Hypokalemia and Hyperglycemia </title>
                     <text>
                        <paragraph>Beta-adrenergic agonist therapies may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. Beta-agonist therapies may produce transient hyperglycemia in some patients. In 4 clinical trials of 6-month duration evaluating umeclidinium and vilanterol ELLIPTA in subjects with COPD, there was no evidence of a treatment effect on serum glucose or potassium.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3bc14777-1960-40e6-8acb-8df221ce14d5">
               <id root="b3412c23-b544-4c73-b4b9-8d0d3ab2018e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Serious asthma-related events–hospitalizations, intubations, death <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_d5ab7664-739f-4bf6-974e-42cb02984dbc">5.1</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Paradoxical bronchospasm <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_de2b81e6-745f-4002-a8fd-82e7f4e278d5">5.5</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Cardiovascular effects <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_5c924790-f375-4ce5-8a1b-7229b1d1b7d7">5.7</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Worsening of narrow-angle glaucoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_bef45778-2b90-49af-9066-2b9c5dd2542e">5.9</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Worsening of urinary retention <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_907ec43d-b6d5-4f5c-aa36-fdf18a15b99e">5.10</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence ≥1% and more common than placebo) are pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, and chest pain. (<linkHtml href="#ID_3758165d-14de-4865-a5aa-0b5f7c78d6ea">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Prasco Laboratories at 1-866-525-0688 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_3758165d-14de-4865-a5aa-0b5f7c78d6ea">
                     <id root="da019a6a-cc83-485a-87fa-9d5d8a8f2065"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The clinical program for umeclidinium and vilanterol ELLIPTA included 8,138 subjects with COPD in four 6‑month lung function trials, one 12-month long-term safety study, and 9 other trials of shorter duration. A total of 1,124 subjects have received at least 1 dose of umeclidinium and vilanterol ELLIPTA (umeclidinium/vilanterol 62.5/25 mcg), and 1,330 subjects have received a higher dose of umeclidinium/vilanterol (125/25 mcg). The safety data described below are based on the four 6-month and one 12-month trials. Adverse reactions observed in the other trials were similar to those observed in the confirmatory trials.</paragraph>
                        <paragraph>
                           <content styleCode="underline">6-Month Trials</content>
                        </paragraph>
                        <paragraph>The incidence of adverse reactions associated with umeclidinium and vilanterol ELLIPTA in <linkHtml href="#_Ref182296618">Table 1</linkHtml> is based on four 6-month trials: 2 placebo-controlled trials (Trial 1 and Trial 2); N = 1,532 and N = 1,489, respectively) and 2 active-controlled trials (Trial 3 and Trial 4); N = 843 and N = 869, respectively). Of the 4,733 subjects, 68% were male and 84% were white. They had a mean age of 63 years and an average smoking history of 45 pack-years, with 50% identified as current smokers. At screening, the mean postbronchodilator percent predicted forced expiratory volume in 1 second (FEV<sub>1</sub>) was 48% (range: 13% to 76%), the mean postbronchodilator FEV<sub>1</sub>/forced vital capacity (FVC) ratio was 0.47 (range: 0.13 to 0.78), and the mean percent reversibility was 14% (range: -45% to 109%).</paragraph>
                        <paragraph>Subjects received 1 dose once daily of the following: umeclidinium and vilanterol ELLIPTA, umeclidinium/vilanterol 125/25 mcg, umeclidinium 62.5 mcg, umeclidinium 125 mcg, vilanterol 25 mcg, active control, or placebo.</paragraph>
                        <table ID="_Ref182296618" width="100%">
                           <caption>Table 1. Adverse Reactions with Umeclidinium and Vilanterol ELLIPTA with ≥1% Incidence and More Common than Placebo in Subjects with Chronic Obstructive Pulmonary Disease</caption>
                           <col width="32%"/>
                           <col width="18%"/>
                           <col width="18%"/>
                           <col width="16%"/>
                           <col width="15%"/>
                           <tbody>
                              <tr>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Umeclidinium and Vilanterol ELLIPTA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 842)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Umeclidinium</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">62.5 mcg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 418)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Vilanterol</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">25 mcg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 1,034)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 555)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule ">
                                    <paragraph>Infections and infestations</paragraph>
                                 </td>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule ">
                                    <paragraph>     Pharyngitis</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule ">
                                    <paragraph>     Sinusitis</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>     Lower respiratory tract infection</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule ">
                                    <paragraph>Gastrointestinal disorders</paragraph>
                                 </td>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule ">
                                    <paragraph>     Constipation</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>     Diarrhea</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule ">
                                    <paragraph>Musculoskeletal and connective tissue disorders</paragraph>
                                 </td>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule ">
                                    <paragraph>     Pain in extremity</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule ">
                                    <paragraph>     Muscle spasms</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>     Neck pain</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule ">
                                    <paragraph>General disorders and administration site conditions</paragraph>
                                 </td>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                                 <td valign="bottom" styleCode="Rrule Lrule Toprule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Botrule Lrule ">
                                    <paragraph>     Chest pain</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule ">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule ">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other adverse reactions with umeclidinium and vilanterol ELLIPTA observed with an incidence &lt;1% but more common than placebo included the following: productive cough, dry mouth, dyspepsia, abdominal pain, gastroesophageal reflux disease, vomiting, musculoskeletal chest pain, chest discomfort, asthenia, atrial fibrillation, ventricular extrasystoles, supraventricular extrasystoles, myocardial infarction, pruritus, rash, and conjunctivitis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">12-Month Trial</content>
                        </paragraph>
                        <paragraph>In a long-term safety trial (Trial 5), 335 subjects were treated for up to 12 months with umeclidinium/vilanterol 125/25 mcg or placebo. The demographic and baseline characteristics of the long-term safety trial were similar to those of the placebo‑controlled efficacy trials described above. Adverse reactions observed with a frequency of ≥1% in the group receiving umeclidinium/vilanterol 125/25 mcg that exceeded that in placebo in this trial were: headache, back pain, sinusitis, cough, urinary tract infection, arthralgia, nausea, vertigo, abdominal pain, pleuritic pain, viral respiratory tract infection, toothache, and diabetes mellitus.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_60c285b5-e3e1-4484-b283-5a09a21f6da0">
                     <id root="6f133058-389c-4ae6-bda7-feb1fb5c6e75"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postapproval use of umeclidinium and vilanterol ELLIPTA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to umeclidinium and vilanterol ELLIPTA or a combination of these factors.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Disorders</content>
                        </paragraph>
                        <paragraph>Palpitations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Eye Disorders</content>
                        </paragraph>
                        <paragraph>Blurred vision, eye pain, glaucoma, increased intraocular pressure.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune System Disorders</content>
                        </paragraph>
                        <paragraph>Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Nervous System Disorders</content>
                        </paragraph>
                        <paragraph>Dysgeusia, tremor.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Psychiatric Disorders</content>
                        </paragraph>
                        <paragraph>Anxiety.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Renal and Urinary Disorders</content>
                        </paragraph>
                        <paragraph>Dysuria, urinary retention.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Respiratory, Thoracic, and Mediastinal Disorders</content>
                        </paragraph>
                        <paragraph>Dysphonia, paradoxical bronchospasm.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_94bcecad-a763-4617-97b2-bfa59e20aca9">
               <id root="5573a663-2eef-43b3-a408-4d39217171f7"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20241122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole): Use with caution. May cause cardiovascular effects. (<linkHtml href="#ID_33db6343-f676-4060-99d3-e5c34280d265">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (<linkHtml href="#ID_d5b21757-8de2-4c1d-880c-5bf7b1579a06">7.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (<linkHtml href="#ID_c871ff69-9157-47e2-9c69-ca2e942d84d7">7.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with non–potassium-sparing diuretics may worsen with concomitant beta-agonists. (<linkHtml href="#ID_77a8a791-c236-48d9-8592-c6c792c4c916">7.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs. (<linkHtml href="#ID_176f902b-467a-4658-b710-bdfc9064b3e2">7.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_33db6343-f676-4060-99d3-e5c34280d265">
                     <id root="5327d97d-6b51-4a2f-9b61-cd4b68b2c75e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Inhibitors of Cytochrome P450 3A4 </title>
                     <text>
                        <paragraph>Vilanterol is a substrate of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the systemic exposure to vilanterol. Caution should be exercised when considering the coadministration of Umeclidinium and Vilanterol ELLIPTA with ketoconazole and other known strong CYP3A4 inhibitors <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_3d3b7131-9c57-400e-877d-64b91012e7fd">5.4</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_1fbb18d8-0022-4654-82d3-a564b203ac81">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d5b21757-8de2-4c1d-880c-5bf7b1579a06">
                     <id root="41002f5d-df3c-4de0-a7fc-106e4499a9b8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, and QTc Prolonging Drugs </title>
                     <text>
                        <paragraph>Vilanterol, like other beta<sub>2</sub>-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c871ff69-9157-47e2-9c69-ca2e942d84d7">
                     <id root="a86d6289-9d47-41a8-b614-1e63326dcb3c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3	Beta-Adrenergic Receptor Blocking Agents </title>
                     <text>
                        <paragraph>Beta-blockers not only block the pulmonary effect of beta-agonists, such as vilanterol, but may also produce severe bronchospasm in patients with COPD. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, there may be no acceptable alternatives to the use of beta‑adrenergic blocking agents for these patients; cardioselective beta-blockers could be considered, although they should be administered with caution.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_77a8a791-c236-48d9-8592-c6c792c4c916">
                     <id root="2ee8ec44-9778-4ca3-8e12-ff3240569d9d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4	Non–Potassium-Sparing Diuretics </title>
                     <text>
                        <paragraph>The electrocardiographic changes and/or hypokalemia that may result from the administration of non–potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with non–potassium-sparing diuretics.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_176f902b-467a-4658-b710-bdfc9064b3e2">
                     <id root="3528a276-0984-4ea9-a078-f885297461b2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5	Anticholinergics </title>
                     <text>
                        <paragraph>There is potential for an additive interaction with concomitantly used anticholinergic medicines. Therefore, avoid coadministration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_bef45778-2b90-49af-9066-2b9c5dd2542e">5.9</linkHtml>, <linkHtml href="#ID_907ec43d-b6d5-4f5c-aa36-fdf18a15b99e">5.10</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_73f83e43-4b83-43fb-99a1-778560ab87c0">
               <id root="2bbc27ee-c85f-4f9e-9f96-2f86444910c8"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20241122"/>
               <component>
                  <section ID="ID_d7926748-aeac-4f36-9528-3bbe8ada11ab">
                     <id root="a4d1debd-d4cb-4aaf-b796-bc37d9877482"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are insufficient data on the use of umeclidinium and vilanterol ELLIPTA or its individual components, umeclidinium and vilanterol, in pregnant women to inform a drug-associated risk. <content styleCode="italics">(See Clinical Considerations.)</content> In animal reproduction studies, umeclidinium administered via inhalation or subcutaneously to pregnant rats and rabbits was not associated with adverse effects on embryofetal development at exposures approximately 50 and 200 times, respectively, the human exposure at the maximum recommended human daily inhaled dose (MRHDID). Vilanterol administered via inhalation to pregnant rats and rabbits produced no fetal structural abnormalities at exposures approximately 70 times the MRHDID. <content styleCode="italics">(See Data.)</content>
                        </paragraph>
                        <paragraph>The estimated risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Labor or Delivery:</content> Umeclidinium and Vilanterol ELLIPTA should be used during late gestation and labor only if the potential benefit justifies the potential for risks related to beta-agonists interfering with uterine contractility.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data:</content> The combination of umeclidinium and vilanterol has not been studied in pregnant animals. Studies in pregnant animals have been conducted with umeclidinium and vilanterol individually.</paragraph>
                        <paragraph>
                           <content styleCode="italics">           Umeclidinium:</content> In separate embryofetal developmental studies, pregnant rats and rabbits received umeclidinium during the period of organogenesis at doses up to approximately 50 and 200 times the MRHDID, respectively (on an AUC basis at maternal inhalation doses up to 278 mcg/kg/day in rats and at maternal subcutaneous doses up to 180 mcg/kg/day in rabbits). No evidence of teratogenic effects was observed in either species.</paragraph>
                        <paragraph>In a perinatal and postnatal developmental study in rats, dams received umeclidinium during late gestation and lactation periods with no evidence of effects on offspring development at doses up to approximately 26 times the MRHDID (on an AUC basis at maternal subcutaneous doses up to 60 mcg/kg/day).</paragraph>
                        <paragraph>
                           <content styleCode="italics">           Vilanterol:</content> In separate embryofetal developmental studies, pregnant rats and rabbits received vilanterol during the period of organogenesis at doses up to approximately 13,000 and 450 times, respectively, the MRHDID (on a mcg/m<sup>2</sup> basis at maternal inhalation doses up to 33,700 mcg/kg/day in rats and on an AUC basis at maternal inhaled doses up to 5,740 mcg/kg/day in rabbits). No evidence of structural abnormalities was observed at any dose in rats or in rabbits up to approximately 70 times the MRHDID (on an AUC basis at maternal doses up to 591 mcg/kg/day in rabbits). However, fetal skeletal variations were observed in rabbits at approximately 450 times the MRHDID (on an AUC basis at maternal inhaled or subcutaneous doses of 5,740 or 300 mcg/kg/day, respectively). The skeletal variations included decreased or absent ossification in cervical vertebral centrum and metacarpals.</paragraph>
                        <paragraph>In a perinatal and postnatal developmental study in rats, dams received vilanterol during late gestation and the lactation periods at doses up to approximately 3,900 times the MRHDID (on a mcg/m<sup>2</sup> basis at maternal oral doses up to 10,000 mcg/kg/day). No evidence of effects in offspring development was observed.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7b54fe98-5b0e-4c19-aa6e-6c28f09bf7e4">
                     <id root="17f22593-444d-458a-a2db-3bebb2e88383"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information available on the presence of umeclidinium or vilanterol in human milk, the effects on the breastfed child, or the effects on milk production. Umeclidinium was detected in the plasma of offspring of lactating rats treated with umeclidinium suggesting its presence in maternal milk. <content styleCode="italics">(See Data.)</content> The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Umeclidinium and Vilanterol ELLIPTA and any potential adverse effects on the breastfed child from umeclidinium or vilanterol or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>Subcutaneous administration of umeclidinium to lactating rats at greater than or equal to 60 mcg/kg/day resulted in a quantifiable level of umeclidinium in 2 of 54 pups, which may indicate transfer of umeclidinium in rat milk.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_84423479-5d47-4b31-bc7f-0d0bdf378cca">
                     <id root="83b7fb9b-d2a0-4602-9909-365f0b9c4f04"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of Umeclidinium and Vilanterol ELLIPTA have not been established in pediatric patients. Umeclidinium and Vilanterol ELLIPTA is not indicated for use in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e34a070a-e98f-4bb9-aba6-db19332e6ecf">
                     <id root="fdd7d3c3-2581-4798-8c8f-933a1dd27af8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Based on available data, no adjustment of the dosage of Umeclidinium and Vilanterol ELLIPTA in geriatric patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.</paragraph>
                        <paragraph>Clinical trials of umeclidinium and vilanterol ELLIPTA for COPD included 2,143 subjects aged 65 years and older and 478 subjects aged 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9ac9532e-bf65-4206-81be-62b974d20cb8">
                     <id root="08057812-b3f7-46c7-96c5-e39907345e4f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment </title>
                     <text>
                        <paragraph>Patients with moderate hepatic impairment (Child-Pugh score of 7-9) showed no relevant increases in C<sub>max</sub> or AUC, nor did protein binding differ between subjects with moderate hepatic impairment and their healthy controls. Studies in subjects with severe hepatic impairment have not been performed <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_1fbb18d8-0022-4654-82d3-a564b203ac81">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7b4b3f2d-ff52-47e8-a9ff-c26d0da880b1">
                     <id root="270d9966-5adb-4e4a-a554-e745336d78d6"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment </title>
                     <text>
                        <paragraph>There were no significant increases in either umeclidinium or vilanterol exposure in subjects with severe renal impairment (CrCl &lt;30 mL/min) compared with healthy subjects. No dosage adjustment is required in patients with renal impairment <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_1fbb18d8-0022-4654-82d3-a564b203ac81">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7f8d1c2b-c1ad-4695-b399-26f84f97160a">
               <id root="bbf16ef0-1cec-42a9-b32d-3f5d37ec83e3"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Umeclidinium and Vilanterol ELLIPTA contains both umeclidinium and vilanterol; therefore, the risks associated with overdosage for the individual components described below apply to Umeclidinium and Vilanterol ELLIPTA. Treatment of overdosage consists of discontinuation of Umeclidinium and Vilanterol ELLIPTA together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medicine can produce bronchospasm. Cardiac monitoring is recommended in cases of overdosage.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Umeclidinium</content>
                  </paragraph>
                  <paragraph>High doses of umeclidinium may lead to anticholinergic signs and symptoms.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Vilanterol</content>
                  </paragraph>
                  <paragraph>The expected signs and symptoms with overdosage of vilanterol are those of excessive beta‑adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms of beta-adrenergic stimulation (e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis). As with all inhaled sympathomimetic medicines, cardiac arrest and even death may be associated with an overdose of vilanterol.</paragraph>
               </text>
               <effectiveTime value="20241122"/>
            </section>
         </component>
         <component>
            <section ID="ID_8fa6a58e-4c3b-4661-83ef-08bfab1c4c64">
               <id root="1361cd59-b378-4f39-af82-5db3634bc434"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Umeclidinium and Vilanterol ELLIPTA is an inhalation powder drug product for delivery of a combination of umeclidinium (an anticholinergic) and vilanterol (a LABA) to patients by oral inhalation.</paragraph>
                  <paragraph>Umeclidinium bromide has the chemical name 1-[2-(benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-azoniabicyclo[2.2.2]octane bromide and the following chemical structure:</paragraph>
                  <renderMultiMedia referencedObject="BAFA85B7-2188-4A1C-B993-DEF441647A5D" ID="id-1736546021"/>
                  <paragraph>Umeclidinium bromide is a white powder with a molecular weight of 508.5, and the empirical formula is C<sub>29</sub>H<sub>34</sub>NO<sub>2</sub>•Br (as a quaternary ammonium bromide compound). It is slightly soluble in water.</paragraph>
                  <paragraph>Vilanterol trifenatate has the chemical name triphenylacetic acid-4-{(1<content styleCode="italics">R</content>)-2-[(6-{2-[(2,6-dicholorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1) and the following chemical structure:</paragraph>
                  <renderMultiMedia referencedObject="ID_0595669f-7876-4bb5-8d95-1b448e577fc2" ID="id1622719002"/>
                  <paragraph>Vilanterol trifenatate is a white powder with a molecular weight of 774.8, and the empirical formula is C<sub>24</sub>H<sub>33</sub>Cl<sub>2</sub>NO<sub>5</sub>•C<sub>20</sub>H<sub>16</sub>O<sub>2</sub>. It is practically insoluble in water.</paragraph>
                  <paragraph>Umeclidinium and Vilanterol ELLIPTA is a light grey and red plastic inhaler containing 2 foil blister strips. Each blister on one strip contains a white powder blend of micronized umeclidinium bromide (74.2 mcg equivalent to 62.5 mcg of umeclidinium), magnesium stearate (75 mcg), and lactose monohydrate (to 12.5 mg), and each blister on the other strip contains a white powder blend of micronized vilanterol trifenatate (40 mcg equivalent to 25 mcg of vilanterol), magnesium stearate (125 mcg), and lactose monohydrate (to 12.5 mg). The lactose monohydrate contains milk proteins. After the inhaler is activated, the powder within both blisters is exposed and ready for dispersion into the airstream created by the patient inhaling through the mouthpiece.</paragraph>
                  <paragraph>Under standardized in vitro test conditions, Umeclidinium and Vilanterol ELLIPTA delivers 55 mcg of umeclidinium and 22 mcg of vilanterol per dose when tested at a flow rate of 60 L/min for 4 seconds.</paragraph>
                  <paragraph>In adult subjects with obstructive lung disease and severely compromised lung function (COPD with FEV<sub>1</sub>/FVC &lt;70% and FEV<sub>1</sub> &lt;30% predicted or FEV<sub>1</sub> &lt;50% predicted plus chronic respiratory failure), mean peak inspiratory flow through the ELLIPTA inhaler was 66.5 L/min (range: 43.5 to 81.0 L/min).</paragraph>
                  <paragraph>The actual amount of drug delivered to the lung will depend on patient factors, such as inspiratory flow profile.</paragraph>
               </text>
               <effectiveTime value="20241122"/>
               <component>
                  <observationMedia ID="BAFA85B7-2188-4A1C-B993-DEF441647A5D">
                     <text>Umeclidinium bromide chemical structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_0595669f-7876-4bb5-8d95-1b448e577fc2">
                     <text>Vilanterol trifenatate chemical structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7f4564ee-248d-47ed-8cfd-5f8d6c543ba2">
               <id root="eeb991c2-7faf-408c-aa50-6140c687529c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20241122"/>
               <component>
                  <section ID="ID_831935c7-83ab-491b-a0f7-af3d8892f25e">
                     <id root="273cb607-9c9b-4b38-b2e4-095fbc75f477"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Umeclidinium and Vilanterol ELLIPTA</content>
                        </paragraph>
                        <paragraph>Umeclidinium and Vilanterol ELLIPTA contains both umeclidinium and vilanterol. The mechanisms of action described below for the individual components apply to Umeclidinium and Vilanterol ELLIPTA. These drugs represent 2 different classes of medications (an anticholinergic and a LABA) each having different effects on clinical and physiological indices.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Umeclidinium</content>
                        </paragraph>
                        <paragraph>Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of umeclidinium is predominantly a site-specific effect.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Vilanterol</content>
                        </paragraph>
                        <paragraph>Vilanterol is a LABA. In vitro tests have shown the functional selectivity of vilanterol was similar to salmeterol. The clinical relevance of this in vitro finding is unknown.</paragraph>
                        <paragraph>Although beta<sub>2</sub>-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta<sub>1</sub>-receptors are the predominant receptors in the heart, there are also beta<sub>2</sub>-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta<sub>2</sub>-agonists may have cardiac effects.</paragraph>
                        <paragraph>The pharmacologic effects of beta<sub>2</sub>-adrenergic agonist drugs, including vilanterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_dfbed26b-6d5d-4a41-bf31-7eb1f792c677">
                     <id root="4241b33f-db0b-4ea5-8b9f-27eadbf3038b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Healthy Subjects: </content>QTc interval prolongation was studied in a double-blind, multiple-dose, placebo- and positive-controlled crossover study in 86 healthy subjects. The maximum mean (95% upper confidence bound) difference in QTcF from placebo after baseline correction was 4.6 (7.1) milliseconds and 8.2 (10.7) milliseconds for umeclidinium/vilanterol 125/25 mcg and umeclidinium/vilanterol 500/100 mcg (8/4 times the recommended dosage), respectively.</paragraph>
                        <paragraph>A dose-dependent increase in heart rate was also observed. The maximum mean (95% upper confidence bound) difference in heart rate from placebo after baseline correction was 8.8 (10.5) beats/min and 20.5 (22.3) beats/min seen 10 minutes after dosing for umeclidinium/vilanterol 125/25 mcg and umeclidinium/vilanterol 500/100 mcg, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Subjects with Chronic Obstructive Pulmonary Disease:</content> The effect of Umeclidinium and Vilanterol ELLIPTA on cardiac rhythm in subjects diagnosed with COPD was assessed using 24-hour Holter monitoring in 6- and 12‑month trials: 53 subjects received umeclidinium and vilanterol ELLIPTA, 281 subjects received umeclidinium/vilanterol 125/25 mcg, and 182 subjects received placebo. No clinically meaningful effects on cardiac rhythm were observed.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1fbb18d8-0022-4654-82d3-a564b203ac81">
                     <id root="b355ffbf-8448-4dc3-8d7a-eaf75ae30f23"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Linear pharmacokinetics was observed for umeclidinium (62.5 to 500 mcg) and vilanterol (25 to 100 mcg).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Umeclidinium:</content> Umeclidinium plasma levels may not predict therapeutic effect. Following inhaled administration of umeclidinium in healthy subjects, C<sub>max</sub> occurred at 5 to 15 minutes. Umeclidinium is mostly absorbed from the lung after inhaled doses with minimum contribution from oral absorption. Following repeat dosing of inhaled umeclidinium and vilanterol ELLIPTA, steady state was achieved within 14 days with up to 1.8-fold accumulation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vilanterol:</content> Vilanterol plasma levels may not predict therapeutic effect. Following inhaled administration of vilanterol in healthy subjects, C<sub>max</sub> occurred at 5 to 15 minutes. Vilanterol is mostly absorbed from the lung after inhaled doses with negligible contribution from oral absorption. Following repeat dosing of inhaled umeclidinium and vilanterol ELLIPTA, steady state was achieved within 14 days with up to 1.7-fold accumulation.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Umeclidinium:</content> Following intravenous administration to healthy subjects, the mean volume of distribution was 86 L. In vitro plasma protein binding in human plasma was on average 89%.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vilanterol:</content> Following intravenous administration to healthy subjects, the mean volume of distribution at steady state was 165 L. In vitro plasma protein binding in human plasma was on average 94%.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism: Umeclidinium: </content>In vitro data showed that umeclidinium is primarily metabolized by the enzyme cytochrome P450 2D6 (CYP2D6) and is a substrate for the P-glycoprotein (P-gp) transporter. The primary metabolic routes for umeclidinium are oxidative (hydroxylation, O-dealkylation) followed by conjugation (e.g., glucuronidation), resulting in a range of metabolites with either reduced pharmacological activity or for which the pharmacological activity has not been established. Systemic exposure to the metabolites is low.</paragraph>
                        <paragraph>
                           <content styleCode="italics">           Vilanterol:</content> In vitro data showed that vilanterol is metabolized principally by CYP3A4 and is a substrate for the P-gp transporter. Vilanterol is metabolized to a range of metabolites with significantly reduced β<sub>1</sub>- and β<sub>2</sub>-agonist activity.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion: Umeclidinium:</content> The effective half-life after once-daily oral dosing is 11 hours. Following intravenous dosing with radiolabeled umeclidinium, mass balance showed 58% of the radiolabel in the feces and 22% in the urine. The excretion of the drug-related material in the feces following intravenous dosing indicated elimination in the bile. Following oral dosing to healthy male subjects, radiolabel recovered in feces was 92% of the total dose and that in urine was &lt;1% of the total dose, suggesting negligible oral absorption.</paragraph>
                        <paragraph>
                           <content styleCode="italics">           Vilanterol:</content> The effective half-life for vilanterol, as determined from inhalation administration of multiple doses, is 11 hours. Following oral administration of radiolabeled vilanterol, mass balance showed 70% of the radiolabel in the urine and 30% in the feces.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>The effects of renal and hepatic impairment and other intrinsic factors on the pharmacokinetics of umeclidinium and vilanterol are shown in <linkHtml href="#_RefFigure1">Figure 1</linkHtml>. Population pharmacokinetic analysis showed no evidence of a clinically significant effect of age (40 to 93 years) (<linkHtml href="#_RefFigure1">Figure 1</linkHtml>), gender (69% male) (<linkHtml href="#_RefFigure1">Figure 1</linkHtml>), inhaled corticosteroid use (48%), or weight (34 to 161 kg) on systemic exposure of either umeclidinium or vilanterol. In addition, there was no evidence of a clinically significant effect of race.</paragraph>
                        <paragraph ID="_RefFigure1">
                           <content styleCode="bold">Figure 1. Impact of Intrinsic Factors on the Pharmacokinetics (PK) of Umeclidinium (UMEC) and Vilanterol (VI)</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="ID_3954584c-e00e-49ca-9568-50653b97ba6e" ID="id762959586"/>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment:</content> The impact of hepatic impairment on the pharmacokinetics of umeclidinium and vilanterol ELLIPTA has been evaluated in subjects with moderate hepatic impairment (Child‑Pugh score of 7-9). There was no evidence of an increase in systemic exposure to either umeclidinium or vilanterol (C<sub>max</sub> and AUC) (<linkHtml href="#_RefFigure1">Figure 1</linkHtml>). There was no evidence of altered protein binding in subjects with moderate hepatic impairment compared with healthy subjects. Umeclidinium and vilanterol ELLIPTA has not been evaluated in subjects with severe hepatic impairment.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment:</content> The pharmacokinetics of umeclidinium and vilanterol ELLIPTA has been evaluated in subjects with severe renal impairment (CrCl &lt;30 mL/min). Umeclidinium systemic exposure was not increased and vilanterol systemic exposure (AUC<sub>(0-24)</sub>) was 56% higher in subjects with severe renal impairment compared with healthy subjects (<linkHtml href="#_RefFigure1">Figure 1</linkHtml>). There was no evidence of altered protein binding in subjects with severe renal impairment compared with healthy subjects.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>When umeclidinium and vilanterol were administered in combination by the inhaled route, the pharmacokinetic parameters for each component were similar to those observed when each active substance was administered separately.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Inhibitors of Cytochrome P450 3A4:</content> Vilanterol is a substrate of CYP3A4. A double-blind, repeat-dose, 2-way crossover drug interaction trial was conducted in healthy subjects to investigate the pharmacokinetic and pharmacodynamic effects of vilanterol 25 mcg as an inhalation powder with ketoconazole 400 mg. The plasma concentrations of vilanterol were higher after single and repeated doses when coadministered with ketoconazole than with placebo (<linkHtml href="#_RefFigure2">Figure 2</linkHtml>). The increase in vilanterol exposure was not associated with an increase in beta‑agonist–related systemic effects on heart rate or blood potassium.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Inhibitors of Cytochrome P450 2D6:</content> In vitro metabolism of umeclidinium is mediated primarily by CYP2D6. However, no clinically meaningful difference in systemic exposure to umeclidinium (500 mcg) (8 times the approved dose) was observed following repeat daily inhaled dosing in CYP2D6 normal (ultrarapid, extensive, and intermediate metabolizers) and poor metabolizer subjects (<linkHtml href="#_RefFigure1">Figure 1</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Inhibitors of P-glycoprotein:</content> Umeclidinium and vilanterol are both substrates of P‑gp. The effect of the moderate P-gp transporter inhibitor verapamil (240 mg once daily) on the steady-state pharmacokinetics of umeclidinium and vilanterol was assessed in healthy subjects. No effect on umeclidinium or vilanterol C<sub>max</sub> was observed; however, an approximately 1.4-fold increase in umeclidinium AUC was observed with no effect on vilanterol AUC (<linkHtml href="#_RefFigure2">Figure 2</linkHtml>).</paragraph>
                        <paragraph ID="_RefFigure2">
                           <content styleCode="bold">Figure 2. Impact of Extrinsic Factors on the Pharmacokinetics (PK) of Umeclidinium (UMEC) and Vilanterol (VI)</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="A9194E0B-B523-4339-814B-A433C7C247ED" ID="id2030754923"/>
                     </text>
                     <effectiveTime value="20241122"/>
                     <component>
                        <observationMedia ID="ID_3954584c-e00e-49ca-9568-50653b97ba6e">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="A9194E0B-B523-4339-814B-A433C7C247ED">
                           <text>Figure 2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-04.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_255ec2ea-e768-4a17-a687-af47135bd8ad">
               <id root="65304a44-4ea6-492a-9dbf-b1a251eb653b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20241122"/>
               <component>
                  <section ID="ID_740f9e2c-0336-4edd-9f40-1e1ecf678405">
                     <id root="bccb4007-7f0a-4506-af01-b787f059570e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Umeclidinium and Vilanterol ELLIPTA</content>
                        </paragraph>
                        <paragraph>No studies of carcinogenicity, mutagenicity, or impairment of fertility were conducted with umeclidinium and vilanterol ELLIPTA; however, studies are available for the individual components, umeclidinium and vilanterol, as described below.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Umeclidinium</content>
                        </paragraph>
                        <paragraph>Umeclidinium produced no treatment-related increases in the incidence of tumors in 2-year inhalation studies in rats and mice at inhaled doses up to 137 and 295/200 mcg/kg/day (male/female), respectively (approximately 20 and 25/20 times, respectively, the MRHDID for adults on an AUC basis).</paragraph>
                        <paragraph>Umeclidinium tested negative in the following genotoxicity assays: the in vitro Ames assay, in vitro mouse lymphoma assay, and in vivo rat bone marrow micronucleus assay.</paragraph>
                        <paragraph>No evidence of impairment of fertility was observed in male and female rats at subcutaneous doses up to 180 mcg/kg/day and at inhaled doses up to 294 mcg/kg/day, respectively (approximately 100 and 50 times, respectively, the MRHDID for adults on an AUC basis).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Vilanterol</content>
                        </paragraph>
                        <paragraph>In a 2-year carcinogenicity study in mice, vilanterol caused a statistically significant increase in ovarian tubulostromal adenomas in females at an inhaled dose of 29,500 mcg/kg/day (approximately 7,800 times the MRHDID for adults on an AUC basis). No increase in tumors was seen at an inhaled dose of 615 mcg/kg/day (approximately 210 times the MRHDID for adults on an AUC basis).</paragraph>
                        <paragraph>In a 2-year carcinogenicity study in rats, vilanterol caused statistically significant increases in mesovarian leiomyomas in females and shortening of the latency of pituitary tumors at inhaled doses greater than or equal to 84.4 mcg/kg/day (greater than or equal to approximately 20 times the MRHDID for adults on an AUC basis). No tumors were seen at an inhaled dose of 10.5 mcg/kg/day (approximately equal to the MRHDID for adults on an AUC basis).</paragraph>
                        <paragraph>These tumor findings in rodents are similar to those reported previously for other beta-adrenergic agonist drugs. The relevance of these findings to human use is unknown.</paragraph>
                        <paragraph>Vilanterol tested negative in the following genotoxicity assays: the in vitro Ames assay, in vivo rat bone marrow micronucleus assay, in vivo rat unscheduled DNA synthesis (UDS) assay, and in vitro Syrian hamster embryo (SHE) cell assay. Vilanterol tested equivocal in the in vitro mouse lymphoma assay.</paragraph>
                        <paragraph>No evidence of impairment of fertility was observed in male and female rats at inhaled vilanterol doses up to 31,500 and 37,100 mcg/kg/day, respectively (both approximately 5,490 times the MRHDID based on AUC).</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_dca5dd73-ae44-47ef-bd00-cc696944ff3a">
               <id root="e5366c4e-afa9-4c20-8b1e-bac1677091b9"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>The safety and effectiveness of umeclidinium and vilanterol ELLIPTA were evaluated in a clinical development program that included 6 dose-ranging trials, 4 lung function trials of 6 months’ duration (2 placebo controlled and 2 active controlled), two 12-week crossover trials, and a 12-month long‑term safety trial. The efficacy of umeclidinium and vilanterol ELLIPTA is based primarily on the dose-ranging trials in 1,908 subjects with COPD or asthma <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_454fc221-9135-4358-955b-97de9464c690">14.1</linkHtml>)]</content> and the 2 placebo-controlled confirmatory trials, with additional support from the 2 active-controlled and 2 crossover trials in 5,388 subjects with COPD, including chronic bronchitis and/or emphysema <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_f6036819-3bcb-4a5e-baa7-643e4c3ef0a9">14.2</linkHtml>)]</content>. Evidence of efficacy for umeclidinium and vilanterol ELLIPTA on COPD exacerbations was established by the efficacy of the umeclidinium component as part of a fixed-dose combination with an ICS/LABA, as assessed in a 12-month trial in 10,355 subjects <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_f6036819-3bcb-4a5e-baa7-643e4c3ef0a9">14.2</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20241122"/>
               <component>
                  <section ID="ID_454fc221-9135-4358-955b-97de9464c690">
                     <id root="d035de3a-0d92-4b7d-995a-fadddd99af5e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Dose-Ranging Trials </title>
                     <text>
                        <paragraph>Dose selection for umeclidinium and vilanterol ELLIPTA in COPD was based on dose-ranging trials for the individual components, vilanterol and umeclidinium. Based on the findings from these studies, once-daily doses of umeclidinium/vilanterol 62.5/25 mcg and umeclidinium/vilanterol 125/25 mcg were evaluated in the confirmatory COPD trials. <content styleCode="bold">Umeclidinium and Vilanterol ELLIPTA is not indicated for asthma.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Umeclidinium</content>
                        </paragraph>
                        <paragraph>Dose selection for umeclidinium in COPD was supported by a 7-day, randomized, double-blind, placebo-controlled, crossover trial evaluating 4 doses of umeclidinium (15.6 to 125 mcg) or placebo dosed once daily in the morning in 163 subjects with COPD. A dose ordering was observed, with the 62.5- and 125-mcg doses demonstrating larger improvements in FEV<sub>1</sub> over 24 hours compared with the lower doses of 15.6 and 31.25 mcg (<linkHtml href="#_RefFigure3">Figure 3</linkHtml>).</paragraph>
                        <paragraph>The differences in trough FEV<sub>1</sub> from baseline after 7 days for placebo and the 15.6-, 31.25-, 62.5-, and 125-mcg doses were -74 mL (95% CI: -118, -31), 38 mL (95% CI: -6, 83), 27 mL (95% CI: -18, 72), 49 mL (95% CI: 6, 93), and 109 mL (95% CI: 65, 152), respectively. Two additional dose-ranging trials in subjects with COPD demonstrated minimal additional benefit at doses above 125 mcg. The dose-ranging results supported the evaluation of 2 doses of umeclidinium, 62.5 and 125 mcg, in the confirmatory COPD trials to further assess dose response.</paragraph>
                        <paragraph>Evaluations of dosing interval by comparing once- and twice-daily dosing supported selection of a once-daily dosing interval for further evaluation in the confirmatory COPD trials.</paragraph>
                        <paragraph ID="_RefFigure3">
                           <content styleCode="bold">Figure 3. Least Squares (LS) Mean Change from Baseline in Postdose Serial FEV<sub>1</sub> (mL) on Days 1 and 7</content>
                        </paragraph>
                        <paragraph>                                                                             Day 1</paragraph>
                        <renderMultiMedia referencedObject="ACCC8F93-731E-4131-975B-0849D8AB79A6" ID="id-1255745428"/>
                        <paragraph>                                                                             Day 7</paragraph>
                        <renderMultiMedia referencedObject="ID_748c8632-bac0-4839-9be6-00cd53dbe101" ID="id98613964"/>
                        <paragraph>
                           <content styleCode="underline">Vilanterol</content>
                        </paragraph>
                        <paragraph>Dose selection for vilanterol in COPD was supported by a 28-day, randomized, double-blind, placebo-controlled, parallel-group trial evaluating 5 doses of vilanterol (3 to 50 mcg) or placebo dosed in the morning in 602 subjects with COPD. Results demonstrated dose-related increases from baseline in FEV<sub>1</sub> at Day 1 and Day 28 (<linkHtml href="#_RefFigure4">Figure 4</linkHtml>).</paragraph>
                        <paragraph ID="_RefFigure4">
                           <content styleCode="bold">Figure 4. Least Squares (LS) Mean Change from Baseline in Postdose Serial FEV<sub>1</sub> (0</content>‑<content styleCode="bold">24 h) (mL) on Days 1 and 28</content>
                        </paragraph>
                        <paragraph>                                                                             Day 1</paragraph>
                        <renderMultiMedia referencedObject="AC08FA43-F9A7-4434-8355-A5FE6889D103" ID="id-2104332185"/>
                        <paragraph>                                                                             Day 28</paragraph>
                        <renderMultiMedia referencedObject="ID_70e9df0c-2db0-4dd1-a4ac-01dd8decaabb" ID="id-2045897170"/>
                        <paragraph>The differences in trough FEV<sub>1</sub> after Day 28 from baseline for placebo and the 3-, 6.25-, 12.5-, 25-, and 50-mcg doses were 29 mL (95% CI: -8, 66), 120 mL (95% CI: 83, 158), 127 mL (95% CI: 90, 164), 138 mL (95% CI: 101, 176), 166 mL (95% CI: 129, 203), and 194 mL (95% CI: 156, 231), respectively. These results supported the evaluation of vilanterol 25 mcg in the confirmatory trials for COPD.</paragraph>
                        <paragraph>Dose-ranging trials in subjects with asthma evaluated doses from 3 to 50 mcg and 12.5 mcg once-daily versus 6.25 mcg twice-daily dosing frequency. The results supported the selection of the vilanterol 25 mcg once-daily dose for further evaluation in the confirmatory trials for COPD.</paragraph>
                     </text>
                     <effectiveTime value="20241122"/>
                     <component>
                        <observationMedia ID="ACCC8F93-731E-4131-975B-0849D8AB79A6">
                           <text>Figure 3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-05.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="ID_748c8632-bac0-4839-9be6-00cd53dbe101">
                           <text>Figure 3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-06.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="AC08FA43-F9A7-4434-8355-A5FE6889D103">
                           <text>Figure 4</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-07.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="ID_70e9df0c-2db0-4dd1-a4ac-01dd8decaabb">
                           <text>Figure 4</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-08.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_f6036819-3bcb-4a5e-baa7-643e4c3ef0a9">
                     <id root="c0cf6aa9-088e-4eac-89d6-e7bceba7f58c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Confirmatory Trials </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lung Function</content>
                        </paragraph>
                        <paragraph>The clinical development program for umeclidinium and vilanterol ELLIPTA included two 6-month, randomized, double-blind, placebo-controlled, parallel-group trials; two 6-month active-controlled trials; and two 12-week crossover trials in subjects with COPD designed to evaluate the efficacy of umeclidinium and vilanterol ELLIPTA on lung function. The 6-month trials treated 4,733 subjects that had a clinical diagnosis of COPD, were 40 years of age or older, had a history of smoking ≥10 pack-years, had a post-albuterol FEV<sub>1</sub> ≤70% of predicted normal values, had a ratio of FEV<sub>1</sub>/FVC of &lt;0.7, and had a Modified Medical Research Council (mMRC) score ≥2. Of the 4,713 subjects included in the efficacy analysis, 68% were male and 84% were white. They had a mean age of 63 years and an average smoking history of 45 pack-years, with 50% identified as current smokers. At screening, the mean postbronchodilator percent predicted FEV<sub>1</sub> was 48% (range: 13% to 76%), the mean postbronchodilator FEV<sub>1</sub>/FVC ratio was 0.47 (range: 0.13 to 0.78), and the mean percent reversibility was 14% (range: -36% to 109%).</paragraph>
                        <paragraph>Trial 1 (NCT01313650) evaluated umeclidinium and vilanterol ELLIPTA (umeclidinium/vilanterol 62.5/25 mcg), umeclidinium 62.5 mcg, vilanterol 25 mcg, and placebo. The primary endpoint was change from baseline in trough (predose) FEV<sub>1</sub> at Day 169 (defined as the mean of the FEV<sub>1</sub> values obtained at 23 and 24 hours after the previous dose on Day 168) compared with placebo, umeclidinium 62.5 mcg, and vilanterol 25 mcg. The comparison of umeclidinium and vilanterol ELLIPTA with umeclidinium 62.5 mcg and vilanterol 25 mcg was assessed to evaluate the contribution of the individual comparators to umeclidinium and vilanterol ELLIPTA. Umeclidinium and vilanterol ELLIPTA demonstrated a larger increase in mean change from baseline in trough (predose) FEV<sub>1</sub> relative to placebo, umeclidinium 62.5 mcg, and vilanterol 25 mcg (<linkHtml href="#_Ref182296683">Table 2</linkHtml>).</paragraph>
                        <table ID="_Ref182296683" width="100%">
                           <caption>Table 2. Least Squares Mean Change from Baseline in Trough FEV<sub>1</sub> (mL) at Day 169 in the Intent-to-Treat Population (Trial 1)</caption>
                           <col width="24%"/>
                           <col width="10%"/>
                           <col width="24%"/>
                           <col width="22%"/>
                           <col width="22%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="5">n = Number in intent-to-treat population.</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="5">
                                    <sup>a</sup> The umeclidinium and vilanterol comparators used the same inhaler and excipients as umeclidinium and vilanterol ELLIPTA.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="3" align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Treatment</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="3" align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">n</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="3" align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Trough FEV<sub>1</sub> (mL) at Day 169</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Difference from</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(95% CI)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n = 280</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Umeclidinium</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">62.5 mcg<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(95% CI)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n = 418</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Vilanterol</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">25 mcg<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(95% CI)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n = 421</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>Umeclidinium and Vilanterol ELLIPTA</paragraph>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>413</paragraph>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>167</paragraph>
                                    <paragraph>(128, 207)</paragraph>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>52</paragraph>
                                    <paragraph>(17, 87)</paragraph>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>95</paragraph>
                                    <paragraph>(60, 130)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Trial 2 (NCT01313637) had a similar study design as Trial 1 but evaluated umeclidinium/vilanterol 125/25 mcg, umeclidinium 125 mcg, vilanterol 25 mcg, and placebo. Results for umeclidinium/vilanterol 125/25 mcg in Trial 2 were similar to those observed for umeclidinium and vilanterol ELLIPTA in Trial 1.</paragraph>
                        <paragraph>Results from the 2 active-controlled trials and the two 12-week trials provided additional support for the efficacy of umeclidinium and vilanterol ELLIPTA in terms of change from baseline in trough FEV<sub>1</sub> compared with the single-ingredient comparators and placebo.</paragraph>
                        <paragraph>Serial spirometric evaluations throughout the 24-hour dosing interval were performed in a subset of subjects (n = 197) at Days 1, 84, and 168 in Trial 1. Results from Trial 1 at Day 1 and Day 168 are shown in <linkHtml href="#_RefFigure5">Figure 5</linkHtml>.</paragraph>
                        <paragraph ID="_RefFigure5">
                           <content styleCode="bold">Figure 5. Least Squares (LS) Mean Change from Baseline in FEV<sub>1</sub> (mL) over Time (0</content>‑<content styleCode="bold">24 h) on Days 1 and 168 (Trial 1 Subset Population)</content>
                        </paragraph>
                        <paragraph>                                                                             Day 1</paragraph>
                        <renderMultiMedia referencedObject="ID_5f9f5373-e73d-4545-b1d8-7270b55f595e" ID="id1715161147"/>
                        <paragraph>                                                                             Day 168</paragraph>
                        <renderMultiMedia referencedObject="ID_94c0cca7-4610-4ce7-8e8e-3231bfacc369" ID="id1385300228"/>
                        <paragraph>The peak FEV<sub>1</sub> was defined as the maximum FEV<sub>1</sub> recorded within 6 hours after the dose of trial medicine on Days 1, 28, 84, and 168 (measurements recorded at 15 and 30 minutes and 1, 3, and 6 hours). The mean peak FEV<sub>1</sub> improvement from baseline for umeclidinium and vilanterol ELLIPTA compared with placebo at Day 1 and at Day 168 was 167 and 224 mL, respectively. The median time to onset on Day 1, defined as a 100-mL increase from baseline in FEV<sub>1</sub>, was 27 minutes in subjects receiving umeclidinium and vilanterol ELLIPTA.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Exacerbations</content>
                        </paragraph>
                        <paragraph>In Trial 6 (NCT02164513), a total of 10,355 subjects with COPD with a history of 1 or more moderate or severe exacerbations in the prior 12 months were randomized (1:2:2) to receive umeclidinium and vilanterol ELLIPTA (n = 2,070), fluticasone furoate/umeclidinium/vilanterol 100/62.5/25 mcg (n = 4,151), or fluticasone furoate/vilanterol 100/25 mcg (n = 4,134) administered once daily in a 12-month trial. The population demographics across all treatments were: mean age of 65 years, 77% white, 66% male, and an average smoking history of 46.6 pack-years, with 35% identified as current smokers. At trial entry, the most common COPD medications were ICS + anticholinergic + LABA (34%), ICS + LABA (26%), anticholinergic + LABA (8%), and anticholinergic (7%). The mean postbronchodilator percent predicted FEV<sub>1</sub> was 46% (standard deviation: 15%), the mean postbronchodilator FEV<sub>1</sub>/FVC ratio was 0.47 (standard deviation: 0.12), and the mean percent reversibility was 10% (range: -59% to 125%).</paragraph>
                        <paragraph>The primary endpoint was annual rate of on-treatment moderate and severe exacerbations in subjects treated with fluticasone furoate/umeclidinium/vilanterol compared with the fixed-dose combinations of fluticasone furoate/vilanterol and umeclidinium and vilanterol ELLIPTA. Exacerbations were defined as worsening of 2 or more major symptoms (dyspnea, sputum volume, and sputum purulence) or worsening of any 1 major symptom together with any 1 of the following minor symptoms: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, and increased cough or wheeze for at least 2 consecutive days. Exacerbations were considered to be of moderate severity if treatment with systemic corticosteroids and/or antibiotics was required and were considered to be severe if resulted in hospitalization or death.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Contribution of Umeclidinium on COPD Exacerbations:</content> Evidence of efficacy for umeclidinium and vilanterol ELLIPTA on COPD exacerbations was established by the efficacy of the umeclidinium component of fluticasone furoate/umeclidinium/vilanterol in Trial 6. Treatment with fluticasone furoate/umeclidinium/vilanterol statistically significantly reduced the on-treatment annual rate of moderate/severe exacerbations by 15% compared with fluticasone furoate/vilanterol (<linkHtml href="#_Ref182296730">Table 3</linkHtml>). A reduction in risk of on-treatment moderate/severe exacerbation (as measured by time to first) was also observed for the same comparison. The benefit of umeclidinium on exacerbations is not expected to diminish when combined with vilanterol in umeclidinium and vilanterol ELLIPTA.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Umeclidinium and Vilanterol ELLIPTA and COPD Exacerbations:</content> In Trial 6, the primary efficacy analysis of the rate of moderate/severe exacerbations, treatment with fluticasone furoate/umeclidinium/vilanterol statistically significantly reduced the on-treatment annual rate of moderate/severe exacerbations by 25% compared with umeclidinium and vilanterol ELLIPTA (<linkHtml href="#_Ref182296730">Table 3</linkHtml>).</paragraph>
                        <table ID="_Ref182296730" width="100%" cellpadding="5.75pt">
                           <caption>Table 3. Moderate and Severe Chronic Obstructive Pulmonary Disease Exacerbations (Trial 6)<sup>a</sup>
                           </caption>
                           <col width="18%"/>
                           <col width="11%"/>
                           <col width="22%"/>
                           <col width="19%"/>
                           <col width="19%"/>
                           <col width="13%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="6">FF/UMEC/VI = Fluticasone furoate/umeclidinium/vilanterol 100/62.5/25 mcg, FF/VI = Fluticasone furoate/vilanterol 100/25 mcg, Umeclidinium and vilanterol ELLIPTA = Umeclidinium/vilanterol 62.5/25 mcg.<br/>
                                    <sup>a</sup> On-treatment analyses excluded exacerbation data collected after discontinuation of study treatment. </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Treatment</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">n</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Mean Annual Rate</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(exacerbations/year)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">FF/UMEC/VI Rate Ratio vs. Comparator</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(95% CI)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">% Reduction in Exacerbation Rate</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(95% CI)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="italics">P </content>Value</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>FF/UMEC/VI</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>4,145</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>0.91</paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>FF/VI</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>4,133</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>1.07</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>0.85</paragraph>
                                    <paragraph>(0.80, 0.90)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>15</paragraph>
                                    <paragraph>(10, 20)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="italics">P</content>&lt;0.001</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>Umeclidinium and Vilanterol ELLIPTA</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>2,069</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>1.21</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>0.75</paragraph>
                                    <paragraph>(0.70, 0.81)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>25</paragraph>
                                    <paragraph>(19, 30)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="italics">P</content>&lt;0.001</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241122"/>
                     <component>
                        <observationMedia ID="ID_5f9f5373-e73d-4545-b1d8-7270b55f595e">
                           <text>Figure 5</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-09.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="ID_94c0cca7-4610-4ce7-8e8e-3231bfacc369">
                           <text>Figure 5</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-10.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_19b24011-de5a-4156-9121-c06e5bacd4e3">
               <id root="889da2f8-dd70-4c38-9436-bee25e39a3c8"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Umeclidinium and Vilanterol ELLIPTA is supplied as a disposable light grey and red plastic inhaler containing 2 foil strips, each with 30 blisters. One strip contains umeclidinium (62.5 mcg per blister), and the other strip contains vilanterol (25 mcg per blister). A blister from each strip is used to create 1 dose. The inhaler is packaged in a moisture‑protective foil tray with a desiccant and a peelable lid in the following pack:</paragraph>
                  <paragraph>NDC 66993-134-97	30 inhalations (60 blisters)</paragraph>
                  <paragraph>Store at room temperature between 68°F and 77°F (20°C and 25°C); excursions permitted from 59°F to 86°F (15°C to 30°C) [See USP Controlled Room Temperature]. Store in a dry place away from direct heat or sunlight. Keep out of reach of children.</paragraph>
                  <paragraph>Umeclidinium and Vilanterol ELLIPTA should be stored inside the unopened moisture-protective foil tray and only removed from the tray immediately before initial use. Discard Umeclidinium and Vilanterol ELLIPTA 6 weeks after opening the foil tray or when the counter reads “0” (after all blisters have been used), whichever comes first. The inhaler is not reusable. Do not attempt to take the inhaler apart.</paragraph>
               </text>
               <effectiveTime value="20241122"/>
            </section>
         </component>
         <component>
            <section ID="ID_d9f6a49a-24c9-4f30-a038-653a523bb0f5">
               <id root="87a7f2b1-8514-4fe0-b017-d484255a8469"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Serious Asthma-Related Events</content>
                  </paragraph>
                  <paragraph>Umeclidinium and Vilanterol ELLIPTA is not indicated for the treatment of asthma. Inform patients that LABAs, such as vilanterol (one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA), when used alone (without ICS) for asthma increase the risk of asthma-related hospitalization or asthma-related death. <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#ID_d5ab7664-739f-4bf6-974e-42cb02984dbc">5.1</linkHtml>).]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Not for Acute Symptoms</content>
                  </paragraph>
                  <paragraph>Inform patients that Umeclidinium and Vilanterol ELLIPTA is not meant to relieve acute symptoms of COPD and extra doses should not be used for that purpose. Advise patients to treat acute symptoms with an inhaled, short-acting beta<sub>2</sub>-agonist such as albuterol. Provide patients with such medication and instruct them in how it should be used.</paragraph>
                  <paragraph>Instruct patients to seek medical attention immediately if they experience any of the following:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Decreasing effectiveness of inhaled, short-acting beta<sub>2</sub>-agonists</item>
                     <item>
                        <caption>•</caption>Need for more inhalations than usual of inhaled, short-acting beta<sub>2</sub>-agonists</item>
                     <item>
                        <caption>•</caption>Significant decrease in lung function as outlined by the physician</item>
                  </list>
                  <paragraph>Tell patients they should not stop therapy with Umeclidinium and Vilanterol ELLIPTA without physician/provider guidance since symptoms may recur after discontinuation. <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#ID_2621e6b9-9be8-4231-bc8e-56a543330c04">5.2</linkHtml>).]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Do Not Use Additional Long-Acting Beta<sub>2</sub>-Agonists</content>
                  </paragraph>
                  <paragraph>Instruct patients not to use other LABAs for COPD. <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#ID_bff5ade5-dfa2-43d0-80c1-1dd0e1aa39d9">5.3</linkHtml>).]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Paradoxical Bronchospasm</content>
                  </paragraph>
                  <paragraph>As with other inhaled medicines, Umeclidinium and Vilanterol ELLIPTA can cause paradoxical bronchospasm. If paradoxical bronchospasm occurs, instruct patients to discontinue Umeclidinium and Vilanterol ELLIPTA and contact their healthcare provider right away.<content styleCode="italics"> [See Warnings and Precautions (<linkHtml href="#ID_de2b81e6-745f-4002-a8fd-82e7f4e278d5">5.5</linkHtml>).]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Risks Associated with Beta-Agonist Therapy</content>
                  </paragraph>
                  <paragraph>Inform patients of adverse effects associated with beta<sub>2</sub>-agonists, such as palpitations, chest pain, rapid heart rate, tremor, or nervousness. Instruct patients to consult a healthcare practitioner immediately should any of these signs and symptoms develop. <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#ID_5c924790-f375-4ce5-8a1b-7229b1d1b7d7">5.7</linkHtml>).]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Worsening of Narrow-Angle Glaucoma</content>
                  </paragraph>
                  <paragraph>Instruct patients to be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately if any of these signs or symptoms develop. <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#ID_bef45778-2b90-49af-9066-2b9c5dd2542e">5.9</linkHtml>).]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Worsening of Urinary Retention</content>
                  </paragraph>
                  <paragraph>Instruct patients to be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination). Instruct patients to consult a physician immediately if any of these signs or symptoms develop. <content styleCode="italics">[See Warnings and Precautions (<linkHtml href="#ID_907ec43d-b6d5-4f5c-aa36-fdf18a15b99e">5.10</linkHtml>).]</content>
                  </paragraph>
                  <paragraph>ELLIPTA is a registered trademark of the GSK group of companies.</paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Prasco Laboratories</content>
                     <br/>Mason, OH 45040 USA</paragraph>
                  <paragraph>Manufactured by:<br/>GlaxoSmithKline<br/>Durham, NC 27701</paragraph>
                  <paragraph>ANR-PS:1PI</paragraph>
               </text>
               <effectiveTime value="20241122"/>
            </section>
         </component>
         <component>
            <section ID="ID_745a8b44-6bdd-4c66-9086-18b33c050109">
               <id root="c912ec1f-6714-414b-919d-131a066ee5e1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="41%"/>
                     <col width="30%"/>
                     <col width="29%"/>
                     <tbody>
                        <tr>
                           <td colspan="3" align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Umeclidinium and Vilanterol ELLIPTA (ue-ME-kli-DIN-ee-um vye-lan’-ter-ol e-LIP-ta)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">inhalation powder,</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">for oral inhalation use</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">What is Umeclidinium and Vilanterol ELLIPTA?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Umeclidinium and Vilanterol ELLIPTA combines 2 medicines in 1 inhaler, an anticholinergic medicine (umeclidinium) and a long‑acting beta<sub>2</sub>-adrenergic agonist (LABA) medicine (vilanterol).<list listType="unordered">
                                       <item>
                                          <caption>o</caption>Anticholinergic medicines such as umeclidinium and LABA medicines such as vilanterol help the muscles around the airways in your lungs stay relaxed to prevent symptoms such as wheezing, cough, chest tightness, and shortness of breath. These symptoms can happen when the muscles around the airways tighten. This makes it hard to breathe.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Umeclidinium and Vilanterol ELLIPTA is not used to relieve sudden breathing problems</content> and will not replace a rescue inhaler.</item>
                                 <item>
                                    <caption>•</caption>Umeclidinium and Vilanterol ELLIPTA is a prescription medicine used long term (chronic) to treat people with chronic obstructive pulmonary disease (COPD). COPD is a chronic lung disease that includes chronic bronchitis, emphysema, or both.</item>
                                 <item>
                                    <caption>•</caption>Umeclidinium and Vilanterol ELLIPTA is used as 1 inhalation 1 time each day to improve symptoms of COPD for better breathing and to reduce the number of flare-ups (the worsening of your COPD symptoms for several days).</item>
                                 <item>
                                    <caption>•</caption>Umeclidinium and Vilanterol ELLIPTA is not for the treatment of asthma. It is not known if Umeclidinium and Vilanterol ELLIPTA is safe and effective in people with asthma.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Umeclidinium and Vilanterol ELLIPTA should not be used in children.</content>
                              </paragraph>
                              <paragraph>It is not known if Umeclidinium and Vilanterol ELLIPTA is safe and effective in children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Do not use Umeclidinium and Vilanterol ELLIPTA if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>have a severe allergy to milk proteins. Ask your healthcare provider if you are not sure.</item>
                                 <item>
                                    <caption>•</caption>are allergic to umeclidinium, vilanterol, or any of the ingredients in Umeclidinium and Vilanterol ELLIPTA. See the end of this Patient Information for a complete list of ingredients in Umeclidinium and Vilanterol ELLIPTA.</item>
                                 <item>
                                    <caption>•</caption>have asthma.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Before using Umeclidinium and Vilanterol ELLIPTA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>have heart problems.</item>
                                 <item>
                                    <caption>•</caption>have high blood pressure.</item>
                                 <item>
                                    <caption>•</caption>have seizures.</item>
                                 <item>
                                    <caption>•</caption>have thyroid problems.</item>
                                 <item>
                                    <caption>•</caption>have diabetes.</item>
                                 <item>
                                    <caption>•</caption>have liver problems.</item>
                                 <item>
                                    <caption>•</caption>have eye problems such as glaucoma. Umeclidinium and Vilanterol ELLIPTA may make your glaucoma worse.</item>
                                 <item>
                                    <caption>•</caption>are allergic to milk proteins.</item>
                                 <item>
                                    <caption>•</caption>have prostate or bladder problems, or problems passing urine. Umeclidinium and Vilanterol ELLIPTA may make these problems worse.</item>
                                 <item>
                                    <caption>•</caption>are pregnant or plan to become pregnant. It is not known if Umeclidinium and Vilanterol ELLIPTA may harm your unborn baby.</item>
                                 <item>
                                    <caption>•</caption>are breastfeeding or plan to breastfeed. It is not known if the medicines in Umeclidinium and Vilanterol ELLIPTA pass into your breast milk and if they can harm your baby.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Umeclidinium and Vilanterol ELLIPTA and certain other medicines may interact with each other. This may cause serious side effects.</paragraph>
                              <paragraph>Especially tell your healthcare provider if you take:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>anticholinergics (including tiotropium, ipratropium, aclidinium)</item>
                                 <item>
                                    <caption>•</caption>atropine</item>
                                 <item>
                                    <caption>•</caption>other LABAs (including salmeterol, formoterol, arformoterol, olodaterol, and indacaterol)</item>
                                 <item>
                                    <caption>•</caption>antifungal or anti-HIV medicines</item>
                              </list>
                              <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">How should I use Umeclidinium and Vilanterol ELLIPTA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Read the step-by-step instructions for using Umeclidinium and Vilanterol ELLIPTA at the end of this Patient Information.</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> use Umeclidinium and Vilanterol ELLIPTA unless your healthcare provider has taught you how to use the inhaler and you understand how to use it correctly.</item>
                                 <item>
                                    <caption>•</caption>Use Umeclidinium and Vilanterol ELLIPTA exactly as your healthcare provider tells you to use it. <content styleCode="bold">Do not</content> use Umeclidinium and Vilanterol ELLIPTA more often than prescribed.</item>
                                 <item>
                                    <caption>•</caption>Use 1 inhalation of Umeclidinium and Vilanterol ELLIPTA 1 time each day. Use Umeclidinium and Vilanterol ELLIPTA at the same time each day.</item>
                                 <item>
                                    <caption>•</caption>If you miss a dose of Umeclidinium and Vilanterol ELLIPTA, take it as soon as you remember. Do not take more than 1 inhalation per day. Take your next dose at your usual time. Do not take 2 doses at 1 time.</item>
                                 <item>
                                    <caption>•</caption>If you take too much Umeclidinium and Vilanterol ELLIPTA, call your healthcare provider or go to the nearest hospital emergency room right away if you have any unusual symptoms, such as worsening shortness of breath, chest pain, increased heart rate, or shakiness.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not use other medicines that contain a LABA or an anticholinergic for any reason.</content> Ask your healthcare provider or pharmacist if any of your other medicines are LABA or anticholinergic medicines.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> stop using Umeclidinium and Vilanterol ELLIPTA unless told to do so by your healthcare provider because your symptoms might get worse. Your healthcare provider will change your medicines as needed.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Umeclidinium and Vilanterol ELLIPTA does not relieve sudden symptoms of COPD and you should not take extra doses of Umeclidinium and Vilanterol ELLIPTA to relieve these sudden symptoms.</content> Always have a rescue inhaler with you to treat sudden symptoms. If you do not have a rescue inhaler, call your healthcare provider to have one prescribed for you.</item>
                                 <item>
                                    <caption>•</caption>Call your healthcare provider or get medical care right away if: <list listType="unordered">
                                       <item>
                                          <caption>o</caption>your breathing problems get worse. </item>
                                       <item>
                                          <caption>o</caption>you need to use your rescue inhaler more often than usual. </item>
                                       <item>
                                          <caption>o</caption>your rescue inhaler does not work as well to relieve your symptoms.</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule ">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of Umeclidinium and Vilanterol ELLIPTA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Umeclidinium and Vilanterol ELLIPTA can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">serious problems in people with asthma.</content> People with asthma who take LABA medicines, such as vilanterol (one of the medicines in Umeclidinium and Vilanterol ELLIPTA), without also using a medicine called an inhaled corticosteroid, have an increased risk of serious problems from asthma, including death.<list listType="unordered">
                                       <item>
                                          <caption>o</caption>Call your healthcare provider if breathing problems worsen over time while using Umeclidinium and Vilanterol ELLIPTA. You may need a different treatment.</item>
                                       <item>
                                          <caption>o</caption>
                                          <content styleCode="bold">Get emergency medical care if: </content>
                                          <list listType="unordered">
                                             <item>
                                                <caption>•</caption>your breathing problems worsen quickly.</item>
                                             <item>
                                                <caption>•</caption>you use your rescue inhaler medicine, but it does not relieve your breathing problems.</item>
                                          </list>
                                       </item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">COPD symptoms that get worse over time.</content> If your COPD symptoms worsen over time, do not increase your dose of Umeclidinium and Vilanterol ELLIPTA; instead call your healthcare provider.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">symptoms of using too much of a LABA medicine, including:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>chest pain</item>
                                 <item>
                                    <caption>o</caption>fast or irregular heartbeat</item>
                                 <item>
                                    <caption>o</caption>tremor</item>
                              </list>
                           </td>
                           <td colspan="2" valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>increased blood pressure</item>
                                 <item>
                                    <caption>o</caption>headache</item>
                                 <item>
                                    <caption>o</caption>nervousness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">sudden breathing problems immediately after inhaling your medicine.</content> If you have sudden breathing problems immediately after inhaling your medicine, stop using Umeclidinium and Vilanterol ELLIPTA and call your healthcare provider right away.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">serious allergic reactions.</content> Call your healthcare provider or get emergency medical care if you get any of the following symptoms of a serious allergic reaction:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>rash</item>
                                 <item>
                                    <caption>o</caption>hives</item>
                              </list>
                           </td>
                           <td colspan="2" valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>swelling of your face, mouth, and tongue</item>
                                 <item>
                                    <caption>o</caption>breathing problems</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">effects on heart.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>increased blood pressure</item>
                                 <item>
                                    <caption>o</caption>a fast or irregular heartbeat, awareness of heartbeat</item>
                              </list>
                           </td>
                           <td colspan="2" valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>chest pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">effects on nervous system.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>tremor</item>
                              </list>
                           </td>
                           <td colspan="2" valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>nervousness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">new or worsening eye problems</content> including acute narrow-angle glaucoma.  You should have regular eye exams while using Umeclidinium and Vilanterol ELLIPTA. Acute narrow-angle glaucoma can cause permanent loss of vision if not treated. Symptoms of acute narrow-angle glaucoma may include:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>eye pain or discomfort</item>
                                 <item>
                                    <caption>o</caption>blurred vision</item>
                                 <item>
                                    <caption>o</caption>red eyes</item>
                              </list>
                           </td>
                           <td colspan="2" valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>nausea or vomiting</item>
                                 <item>
                                    <caption>o</caption>seeing halos or bright colors around lights</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>If you have these symptoms, call your healthcare provider right away before taking another dose.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">urinary retention.</content> People who take Umeclidinium and Vilanterol ELLIPTA may develop new or worse urinary retention. Symptoms of urinary retention may include: </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>difficulty urinating</item>
                                 <item>
                                    <caption>o</caption>urinating frequently</item>
                              </list>
                           </td>
                           <td colspan="2" valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>painful urination</item>
                                 <item>
                                    <caption>o</caption>urination in a weak stream or drips</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>If you have these symptoms of urinary retention, stop taking Umeclidinium and Vilanterol ELLIPTA and call your healthcare provider right away before taking another dose.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">changes in laboratory blood values</content>, including high levels of blood sugar (hyperglycemia) and low levels of potassium (hypokalemia).</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Common side effects of Umeclidinium and Vilanterol ELLIPTA include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>sore throat</item>
                                 <item>
                                    <caption>•</caption>common cold symptoms</item>
                                 <item>
                                    <caption>•</caption>pain in your arms or legs</item>
                                 <item>
                                    <caption>•</caption>chest pain</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>sinus infection</item>
                                 <item>
                                    <caption>•</caption>constipation</item>
                                 <item>
                                    <caption>•</caption>muscle spasms</item>
                              </list>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>lower respiratory infection</item>
                                 <item>
                                    <caption>•</caption>diarrhea</item>
                                 <item>
                                    <caption>•</caption>neck pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>These are not all the possible side effects of Umeclidinium and Vilanterol ELLIPTA.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">How should I store Umeclidinium and Vilanterol ELLIPTA?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Store Umeclidinium and Vilanterol ELLIPTA at room temperature between 68°F and 77°F (20°C and 25°C). Keep in a dry place away from heat and sunlight.</item>
                                 <item>
                                    <caption>•</caption>Store Umeclidinium and Vilanterol ELLIPTA in the unopened tray and only open when ready for use.</item>
                                 <item>
                                    <caption>•</caption>Safely throw away Umeclidinium and Vilanterol ELLIPTA in the trash 6 weeks after you open the tray or when the counter reads “0”, whichever comes first. Write the date you open the tray on the label on the inhaler.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Keep Umeclidinium and Vilanterol ELLIPTA and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of Umeclidinium and Vilanterol ELLIPTA.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Umeclidinium and Vilanterol ELLIPTA for a condition for which it was not prescribed. Do not give Umeclidinium and Vilanterol ELLIPTA to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                              <paragraph>You can ask your healthcare provider or pharmacist for information about Umeclidinium and Vilanterol ELLIPTA that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top" styleCode="Rrule Botrule Lrule ">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in Umeclidinium and Vilanterol ELLIPTA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredients:</content> umeclidinium, vilanterol</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> lactose monohydrate (contains milk proteins), magnesium stearate<br/>
                                 <br/>For more information about Umeclidinium and Vilanterol ELLIPTA, call 1-866-525-0688.</paragraph>
                              <paragraph>ELLIPTA is a registered trademark of the GSK group of companies.<br/>
                                 <br/>Manufactured for:</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Prasco Laboratories</content>
                              </paragraph>
                              <paragraph>Mason, OH 45040 USA</paragraph>
                              <paragraph>Manufactured by:</paragraph>
                              <paragraph>GlaxoSmithKline</paragraph>
                              <paragraph>Durham, NC 27701</paragraph>
                              <paragraph>ANR-PS:1PIL</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>       This Patient Information has been approved by the U.S. Food and Drug Administration       Revised: November 2024</paragraph>
               </text>
               <effectiveTime value="20241122"/>
            </section>
         </component>
         <component>
            <section ID="ID_fa3dad6f-04ce-4996-80cc-1a74b45093bd">
               <id root="932ef51b-b896-4ef7-9cd7-b658da2f8742"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="50%"/>
                     <col width="50%"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                              <paragraph>
                                 <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Umeclidinium and Vilanterol ELLIPTA (ue-ME-kli-DIN-ee-um vye-lan’-ter-ol e-LIP-ta)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">inhalation powder,</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">for oral inhalation use</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule ">
                              <paragraph>
                                 <content styleCode="bold">Read this before you start:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">If you open and close the cover without inhaling the medicine, you will lose the dose.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">The lost dose will be securely held inside the inhaler, but it will no longer be available to be inhaled.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">It is not possible to accidentally take a double dose or an extra dose in 1 inhalation.</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Your Umeclidinium and Vilanterol ELLIPTA inhaler</content>
                              </paragraph>
                              <renderMultiMedia referencedObject="F5FA8464-C12B-4E57-8122-1241075381B3" ID="id-1331750235"/>
                              <paragraph>
                                 <content styleCode="bold">How to use your inhaler</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Umeclidinium and Vilanterol ELLIPTA comes in a tray.</item>
                                 <item>
                                    <caption>•</caption>Peel back the lid to open the tray. See <content styleCode="bold">Figure A</content>.</item>
                                 <item>
                                    <caption>•</caption>The tray contains a desiccant to reduce moisture. Do not eat or inhale. Throw it away in the household trash out of reach of children and pets. See <content styleCode="bold">Figure B</content>.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule ">
                              <renderMultiMedia referencedObject="ID_41298e10-7107-4655-93cf-92aff0f24895" ID="id288017998"/>
                              <paragraph>
                                 <content styleCode="bold">Figure A</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule ">
                              <renderMultiMedia referencedObject="C536D471-2BE7-4F46-A5FF-4F0E6DB9A07F" ID="id-1231456217"/>
                              <paragraph>
                                 <content styleCode="bold">Figure B</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule ">
                              <paragraph>
                                 <content styleCode="bold">Important Notes:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Your inhaler contains 30 doses.</item>
                                 <item>
                                    <caption>•</caption>Each time you fully open the cover of the inhaler (you will hear a clicking sound), a dose is ready to be inhaled. This is shown by a decrease in the number on the counter.</item>
                                 <item>
                                    <caption>•</caption>If you open and close the cover without inhaling the medicine, you will lose the dose. The lost dose will be held in the inhaler, but it will no longer be available to be inhaled. It is not possible to accidentally take a double dose or an extra dose in 1 inhalation.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> open the cover of the inhaler until you are ready to use it. To avoid wasting doses after the inhaler is ready, <content styleCode="bold">do not</content> close the cover until after you have inhaled the medicine.</item>
                                 <item>
                                    <caption>•</caption>Write the “Tray opened” and “Discard” dates on the inhaler label. The “Discard” date is 6 weeks from the date you open the tray.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Check the counter. See Figure C.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule ">
                              <renderMultiMedia referencedObject="ID_038800d9-5df2-476b-adda-d643641c043f" ID="id837807177"/>
                              <paragraph>
                                 <content styleCode="bold">Figure C</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Before the inhaler is used for the first time, the counter should show the number 30. This is the number of doses in the inhaler.</item>
                                 <item>
                                    <caption>•</caption>Each time you open the cover, you prepare 1 dose of medicine.</item>
                                 <item>
                                    <caption>•</caption>The counter counts down by 1 each time you open the cover.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule ">
                              <paragraph>
                                 <content styleCode="bold">Prepare your dose:</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Wait to open the cover until you are ready to take your dose.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule ">
                              <renderMultiMedia referencedObject="AA4CE85C-945F-41AA-B517-6568199B56D0" ID="id-379402638"/>
                              <paragraph>
                                 <content styleCode="bold">Figure D</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <paragraph>
                                 <content styleCode="bold">Step 1.   Open the cover of the inhaler. See Figure D.</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Slide the cover down to expose the mouthpiece. You should hear a “click.” The counter will count down by 1 number. You do not need to shake this kind of inhaler. <content styleCode="bold">Your inhaler is now ready to use.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>If the counter does not count down as you hear the click, the inhaler will not deliver the medicine. Call your healthcare provider or pharmacist if this happens.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule ">
                              <renderMultiMedia referencedObject="C85C947F-3A59-4146-A014-561FCAEEB6CE" ID="id-483700218"/>
                              <paragraph>
                                 <content styleCode="bold">Figure E</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <paragraph>
                                 <content styleCode="bold">Step 2.   Breathe out. See Figure E.</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>While holding the inhaler away from your mouth, breathe out (exhale) fully. Do not breathe out into the mouthpiece.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule ">
                              <renderMultiMedia referencedObject="ID_3c756103-782b-4b3a-b726-6f423b8cac1c" ID="id1593887770"/>
                              <paragraph>
                                 <content styleCode="bold">Figure F</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <paragraph>
                                 <content styleCode="bold">Step 3.   Inhale your medicine. See Figure F.</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Put the mouthpiece between your lips, and close your lips firmly around it. Your lips should fit over the curved shape of the mouthpiece. </item>
                                 <item>
                                    <caption>•</caption>Take 1 long, steady, deep breath in through your mouth. <content styleCode="bold">Do not</content> breathe in through your nose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule ">
                              <renderMultiMedia referencedObject="E6ED4E1F-4D01-4EC6-987F-4CBEF12C9DDC" ID="id-940529081"/>
                              <paragraph>
                                 <content styleCode="bold">Figure G</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Do not block the air vent with your fingers. <content styleCode="bold">See Figure G.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule ">
                              <renderMultiMedia referencedObject="ID_4dc4fe0a-4048-47b9-99e4-396054f7fbee" ID="id-180668224"/>
                              <paragraph>
                                 <content styleCode="bold">Figure H</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Remove the inhaler from your mouth and hold your breath for about 3 to 4 seconds </content>(or as long as comfortable for you). <content styleCode="bold">See Figure H.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule ">
                              <renderMultiMedia referencedObject="ID_6a9bec48-c9e1-466c-8bef-f68051c8b46f" ID="id1366482073"/>
                              <paragraph>
                                 <content styleCode="bold">Figure I</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <paragraph>
                                 <content styleCode="bold">Step 4.   Breathe out slowly and gently. See Figure I. </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>You may not taste or feel the medicine, even when you are using the inhaler correctly. </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> take another dose from the inhaler even if you do not feel or taste the medicine.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Lrule ">
                              <renderMultiMedia referencedObject="C151FACD-DF01-4471-8C50-D3A07F6808C9" ID="id-2044134911"/>
                              <paragraph>
                                 <content styleCode="bold">Figure J</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <paragraph>
                                 <content styleCode="bold">Step 5.   Close the inhaler. See Figure J.</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>You can clean the mouthpiece if needed, using a dry tissue, before you close the cover. Routine cleaning is not required.</item>
                                 <item>
                                    <caption>•</caption>Slide the cover up and over the mouthpiece as far as it will go.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule ">
                              <paragraph>
                                 <content styleCode="bold">Important Note: When should you get a refill?</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Lrule ">
                              <renderMultiMedia referencedObject="A2633608-1DED-4FBE-879F-B30A13A7F254" ID="id-465742540"/>
                              <paragraph>
                                 <content styleCode="bold">Figure K</content>
                                 <br/>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">When you have fewer than 10 doses remaining</content> in your inhaler, the left half of the counter shows red as a reminder to get a refill. <content styleCode="bold">See Figure K.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>After you have inhaled the last dose, the counter will show “0” and will be empty.</item>
                                 <item>
                                    <caption>•</caption>Throw the empty inhaler away in your household trash out of reach of children and pets.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule ">
                              <paragraph>For more information about Umeclidinium and Vilanterol ELLIPTA, call 1-866-525-0688.</paragraph>
                              <paragraph>ELLIPTA is a registered trademark of the GSK group of companies.<br/>
                                 <br/>Manufactured for:</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Prasco Laboratories</content>
                              </paragraph>
                              <paragraph>Mason, OH 45040 USA<br/>
                                 <br/>Manufactured by:</paragraph>
                              <paragraph>GlaxoSmithKline</paragraph>
                              <paragraph>Durham, NC 27701<br/>
                                 <br/>ANR-PS: 1IFU</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Botrule Lrule "/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>     This Instructions for Use has been approved by the U.S. Food and Drug Administration          Revised: November 2024</paragraph>
               </text>
               <effectiveTime value="20241122"/>
               <component>
                  <observationMedia ID="F5FA8464-C12B-4E57-8122-1241075381B3">
                     <text>Umeclidinium and Vilanterol ELLIPTA inhaler parts</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_41298e10-7107-4655-93cf-92aff0f24895">
                     <text>Figure A</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="C536D471-2BE7-4F46-A5FF-4F0E6DB9A07F">
                     <text>Figure B</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_038800d9-5df2-476b-adda-d643641c043f">
                     <text>Figure C</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="AA4CE85C-945F-41AA-B517-6568199B56D0">
                     <text>Figure D</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="C85C947F-3A59-4146-A014-561FCAEEB6CE">
                     <text>Figure E</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_3c756103-782b-4b3a-b726-6f423b8cac1c">
                     <text>Figure F</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="E6ED4E1F-4D01-4EC6-987F-4CBEF12C9DDC">
                     <text>Figure G</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_4dc4fe0a-4048-47b9-99e4-396054f7fbee">
                     <text>Figure H</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_6a9bec48-c9e1-466c-8bef-f68051c8b46f">
                     <text>Figure I</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="C151FACD-DF01-4471-8C50-D3A07F6808C9">
                     <text>Figure J</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="A2633608-1DED-4FBE-879F-B30A13A7F254">
                     <text>Figure K</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_43966109-52cf-42b2-badf-865834f0b23c">
               <id root="ec908bad-e600-4a4b-89c7-c9ee19dd5f88"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 6993-134-97</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Umeclidinium and Vilanterol ELLIPTA Inhalation Powder</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">62.5 mcg/25 mcg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PRASCO</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR ORAL INHALATION ONLY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each blister on one strip contains 62.5 mcg of umeclidinium, magnesium stearate, and lactose monohydrate.  Each blister on the other strip contains 25 mcg of vilanterol, magnesium stearate, and lactose monohydrate.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 ELLIPTA Inhaler containing 30 doses (60 blisters total)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rev. 12/24</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">62000000096475</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="F6CAB6BF-1C66-4FE9-9176-6F7BFC89C941" ID="id-1885853983"/>
               </text>
               <effectiveTime value="20241122"/>
               <component>
                  <observationMedia ID="F6CAB6BF-1C66-4FE9-9176-6F7BFC89C941">
                     <text>Umeclidinium and Vilanterol Ellipta 30 dose carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="umeclidinium-vilanterol-ellipta-spl-graphic-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>